Cover Image
市場調查報告書

Acceleron Pharma, Inc.的產品平台分析

Acceleron Pharma, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 199625
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Acceleron Pharma, Inc.的產品平台分析 Acceleron Pharma, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月30日 內容資訊: 英文 48 Pages
簡介

Acceleron Pharma, Inc.是從事癌症及其他罕見疾病用蛋白質治療藥之藥物研發、開發、製造及商品化的生物醫藥品企業。

本報告提供Acceleron Pharma, Inc.的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,以及暫停中的計劃等資訊。

Acceleron Pharma, Inc.的基本資料

Acceleron Pharma, Inc.概要

  • 主要資訊
  • 企業資料

Acceleron Pharma, Inc.:R&D概要

  • 主要的治療範圍

Acceleron Pharma, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Acceleron Pharma, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Acceleron Pharma, Inc.:藥物簡介

  • dalantercept
  • luspatercept
  • sotatercept
  • ACE-083
  • ACE-661
  • ACE-772
  • ALKS-693
  • 針對骨疾病用蛋白質
  • 線維症的蛋白質
  • 針對肌肉疾病用蛋白質
  • 針對皮膚疾病用蛋白質

Acceleron Pharma, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Acceleron Pharma, Inc.:最近的開發平台趨勢

Acceleron Pharma, Inc.:暫停中的計劃

Acceleron Pharma, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Acceleron Pharma, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08040CDB

Summary

Global Markets Direct's, 'Acceleron Pharma, Inc. - Product Pipeline Review - 2016', provides an overview of the Acceleron Pharma, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Acceleron Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Acceleron Pharma, Inc.
  • The report provides overview of Acceleron Pharma, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Acceleron Pharma, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Acceleron Pharma, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Acceleron Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acceleron Pharma, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acceleron Pharma, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acceleron Pharma, Inc. Snapshot
    • Acceleron Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Acceleron Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Acceleron Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Acceleron Pharma, Inc. - Pipeline Products Glance
    • Acceleron Pharma, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Acceleron Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Acceleron Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Acceleron Pharma, Inc. - Drug Profiles
    • luspatercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalantercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotatercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-083
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-1332
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-2395
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-2494
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-2536
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-2798
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-3891
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-661
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acceleron Pharma, Inc. - Pipeline Analysis
    • Acceleron Pharma, Inc. - Pipeline Products by Target
    • Acceleron Pharma, Inc. - Pipeline Products by Route of Administration
    • Acceleron Pharma, Inc. - Pipeline Products by Molecule Type
    • Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action
  • Acceleron Pharma, Inc. - Recent Pipeline Updates
  • Acceleron Pharma, Inc. - Dormant Projects
  • Acceleron Pharma, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ramatercept
  • Acceleron Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Acceleron Pharma, Inc., Key Information
  • Acceleron Pharma, Inc., Key Facts
  • Acceleron Pharma, Inc. - Pipeline by Indication, 2016
  • Acceleron Pharma, Inc. - Pipeline by Stage of Development, 2016
  • Acceleron Pharma, Inc. - Monotherapy Products in Pipeline, 2016
  • Acceleron Pharma, Inc. - Phase III, 2016
  • Acceleron Pharma, Inc. - Phase II, 2016
  • Acceleron Pharma, Inc. - Phase I, 2016
  • Acceleron Pharma, Inc. - Preclinical, 2016
  • Acceleron Pharma, Inc. - Pipeline by Target, 2016
  • Acceleron Pharma, Inc. - Pipeline by Route of Administration, 2016
  • Acceleron Pharma, Inc. - Pipeline by Molecule Type, 2016
  • Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Acceleron Pharma, Inc. - Recent Pipeline Updates, 2016
  • Acceleron Pharma, Inc. - Dormant Developmental Projects,2016
  • Acceleron Pharma, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Acceleron Pharma, Inc. - Pipeline by Top 10 Indication, 2016
  • Acceleron Pharma, Inc. - Pipeline by Stage of Development, 2016
  • Acceleron Pharma, Inc. - Monotherapy Products in Pipeline, 2016
  • Acceleron Pharma, Inc. - Pipeline by Top 10 Target, 2016
  • Acceleron Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2016
  • Acceleron Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2016
  • Acceleron Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top